337 related articles for article (PubMed ID: 15875189)
41. Patient responsiveness to calcitonin salmon nasal spray: a subanalysis of a 2-year study.
Overgaard K; Lindsay R; Christiansen C
Clin Ther; 1995; 17(4):680-5. PubMed ID: 8565031
[TBL] [Abstract][Full Text] [Related]
42. [Comparison of the effectiveness of 17-beta-estradiol and calcitonin in women with postmenopausal bone loss].
Stĕpán J; Formánková J; Masatová A; Michalský M; Rosenová Z
Cas Lek Cesk; 1997 Apr; 136(8):242-8. PubMed ID: 9264868
[TBL] [Abstract][Full Text] [Related]
43. [Effect of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis].
Liu JL; Zhu HM; Huang QR; Zhang ZL; Li HL; Qin YJ; Zhang Y; Wei DL; Lu JH; Liu H; Chen XP; Liu YJ; Ekangaki A; Zheng YM; Diez-Perez A; Harpe K
Zhonghua Yi Xue Za Zhi; 2004 Feb; 84(4):269-73. PubMed ID: 15059505
[TBL] [Abstract][Full Text] [Related]
44. Suppression of bone resorption in early postmenopausal women by intranasal salmon calcitonin in relation to dosage and basal bone turnover.
Ongphiphadhanakul B; Piaseu N; Chailurkit L; Rajatanavin R
Calcif Tissue Int; 1998 May; 62(5):379-82. PubMed ID: 9541513
[TBL] [Abstract][Full Text] [Related]
45. Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: a prospective study.
Rico H; Revilla M; Hernández ER; Villa LF; Alvarez de Buergo M
Calcif Tissue Int; 1995 Mar; 56(3):181-5. PubMed ID: 7750020
[TBL] [Abstract][Full Text] [Related]
46. Intranasal salmon calcitonin in postmenopausal osteoporosis: effect of different therapeutic regimens on vertebral and peripheral bone density.
Perrone G; Galoppi P; Valente M; Capri O; D'Ubaldo C; Anelli G; Zichella L
Gynecol Obstet Invest; 1992; 33(3):168-71. PubMed ID: 1612530
[TBL] [Abstract][Full Text] [Related]
47. Skeletal effects of cyclic recombinant human growth hormone and salmon calcitonin in osteopenic postmenopausal women.
Holloway L; Kohlmeier L; Kent K; Marcus R
J Clin Endocrinol Metab; 1997 Apr; 82(4):1111-7. PubMed ID: 9100582
[TBL] [Abstract][Full Text] [Related]
48. An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis.
Hodsman AB; Fraher LJ; Ostbye T; Adachi JD; Steer BM
J Clin Invest; 1993 Mar; 91(3):1138-48. PubMed ID: 8450043
[TBL] [Abstract][Full Text] [Related]
49. Effects of a combined alendronate and calcitriol agent (Maxmarvil) on bone metabolism in Korean postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study.
Rhee Y; Kang M; Min Y; Byun D; Chung Y; Ahn C; Baek K; Mok J; Kim D; Kim D; Kim H; Kim Y; Myoung S; Kim D; Lim SK
Osteoporos Int; 2006 Dec; 17(12):1801-7. PubMed ID: 17019520
[TBL] [Abstract][Full Text] [Related]
50. [Effectiveness of intranasal salmon calcitonin treatment in postmenopausal osteoporosis].
Kopaliani M
Georgian Med News; 2005 Apr; (121):38-42. PubMed ID: 15908722
[TBL] [Abstract][Full Text] [Related]
51. A 5-year controlled randomized study of prevention of postmenopausal trabecular bone loss with nasal salmon calcitonin and calcium.
Reginster JY; Meurmans L; Deroisy R; Jupsin I; Biquet I; Albert A; Franchimont P
Eur J Clin Invest; 1994 Aug; 24(8):565-9. PubMed ID: 7982445
[TBL] [Abstract][Full Text] [Related]
52. Bone turnover and density in obese premenopausal women during moderate weight loss and calcium supplementation.
Shapses SA; Von Thun NL; Heymsfield SB; Ricci TA; Ospina M; Pierson RN; Stahl T
J Bone Miner Res; 2001 Jul; 16(7):1329-36. PubMed ID: 11450709
[TBL] [Abstract][Full Text] [Related]
53. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
Ettinger B; San Martin J; Crans G; Pavo I
J Bone Miner Res; 2004 May; 19(5):745-51. PubMed ID: 15068497
[TBL] [Abstract][Full Text] [Related]
54. Prevention of osteoporosis in heart transplant recipients: a comparison of calcitriol with calcitonin and pamidronate.
Bianda T; Linka A; Junga G; Brunner H; Steinert H; Kiowski W; Schmid C
Calcif Tissue Int; 2000 Aug; 67(2):116-21. PubMed ID: 10920215
[TBL] [Abstract][Full Text] [Related]
55. Effect of salmon calcitonin nasal spray on bone mass in patients with high turnover osteoporosis.
Gennari C; Agnusdei D; Camporeale A
Osteoporos Int; 1993; 3 Suppl 1():208-10. PubMed ID: 8461563
[No Abstract] [Full Text] [Related]
56. Effects of salmon calcitonin treatment on serum and synovial fluid bone formation and resorption markers in osteoporosis patients.
Atbinici H; Sipahioğlu S; Aksoy N; Baykara İ; Işıkan UE
Acta Orthop Traumatol Turc; 2015; 49(2):160-5. PubMed ID: 26012937
[TBL] [Abstract][Full Text] [Related]
57. [Salmon calcitonin in osteoporosis. The effect of intranasal application on bone mineral content and fracture frequency in postmenopausal women with manifest osteoporotic changes].
Overgaard K; Ravn P; Hansen MA; Christiansen C
Ugeskr Laeger; 1993 Aug; 155(31):2387-91. PubMed ID: 8346588
[TBL] [Abstract][Full Text] [Related]
58. Effects of chronic liver disease on bone mineral density and bone metabolism markers in postmenopausal women.
Uretmen S; Gol M; Cimrin D; Irmak E
Eur J Obstet Gynecol Reprod Biol; 2005 Nov; 123(1):67-71. PubMed ID: 16051419
[TBL] [Abstract][Full Text] [Related]
59. Treatment of postmenopausal osteoporosis with salmon calcitonin nasal spray: evaluation by bone mineral content and biochemical patterns.
Tolino A; Romano L; Ronsini S; Riccio S; Montemagno U
Int J Clin Pharmacol Ther Toxicol; 1993 Jul; 31(7):358-60. PubMed ID: 8370634
[TBL] [Abstract][Full Text] [Related]
60. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
